Search Results
Sep 08, 2026, 16:45 ET ARES CAPITAL CORPORATION PRICES PUBLIC OFFERING OF $750 MILLION 6.250% UNSECURED NOTES DUE 2033
NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Ares Capital Corporation (Nasdaq: ARCC) announced that it has priced an underwritten public offering of $750 million in aggregate principal amount of 6.250% notes due 2033. The notes will
More news about: Ares Capital Corporation
Jul 29, 2026, 06:00 ET ARES CAPITAL CORPORATION ANNOUNCES JUNE 30, 2026 FINANCIAL RESULTS AND DECLARES THIRD QUARTER 2026 DIVIDEND OF $0.48 PER SHARE
NEW YORK, July 29, 2026 /PRNewswire/ -- Ares Capital Corporation ("Ares Capital") (NASDAQ: ARCC) announced that its Board of Directors has declared a third quarter 2026 dividend of $0.48 per share. The third quarter 2026 dividend is payable on September 30,
More news about: Ares Capital Corporation
Jul 02, 2026, 07:00 ET ARES CAPITAL CORPORATION SCHEDULES EARNINGS RELEASE FOR THE SECOND QUARTER ENDED JUNE 30, 2026
NEW YORK, July 2, 2026 /PRNewswire/ -- Ares Capital Corporation ("Ares Capital") (NASDAQ: ARCC) announced today that it will report earnings for the second quarter ended June 30, 2026 on Wednesday, July 29, 2026 prior to the opening of the Nasdaq
More news about: Ares Capital Corporation
Jun 08, 2026, 07:30 ET ARES CAPITAL CORPORATION ANNOUNCES INAUGURAL $1 BILLION COMMERCIAL PAPER PROGRAM
YORK, June 8, 2026 /PRNewswire/ -- Ares Capital Corporation ("Ares Capital" or the "Company") (NASDAQ: ARCC) announced today the establishment of its inaugural commercial paper program. The program allows the Company to issue up to a maximum aggregate amount
More news about: Ares Capital Corporation
Oct 02, 2025, 08:08 ET Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
Final analysis of lenvatinib + pembrolizumab(L+P) vs sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) withor without bone metastases in CLEAR
More news about: Eisai Inc.